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Abstract: The treatment for tuberculosis infection usually involves a prolonged regimen of multiple
antibacterial drugs, which might lead to various secondary effects. For preventing drug resistance
and side-effects of anti-tuberculosis drugs, new methods for improving the bioavailability of
APIs were investigated. The strategy proposed consists of the preparation of therapeutic deep
eutectic solvents (THEDES), that incorporate L-arginine and ethambutol. The eutectic mixtures
were prepared by mixing the components at a certain molar ratio, until a clear liquid solution
was formed. The prepared mixtures were characterized by differential scanning calorimetry (DSC),
polarized optical microscopy (POM) and nuclear magnetic resonance spectroscopy (1H and 13C-NMR).
The solubility and permeability of the drugs when they are in the THEDES form was evaluated at
37 ◦C, in phosphate buffered saline (PBS). Solubility studies showed an increase of the solubility
of ethambutol when incorporated in the eutectic system. The cytotoxicity was evaluated using a
model cell line (Caco-2), comparing the cytotoxicity of the API incorporated in the eutectic system.
We observed that the cell viability in the THEDES was affected by the presence of citric acid,
and higher cytotoxicity values were observed. Nonetheless, these findings do not compromise
the possibility to use these systems as new delivery systems for ethambutol and arginine.
Keywords: therapeutic deep eutectic solvents; tuberculosis; ethambutol; L-arginine
1. Introduction
Tuberculosis infection caused by Mycobacterium tuberculosis complex, continues to be one of
the major causes of morbidity and mortality worldwide, and the treatment frequently comprises
a combination of multiple antibacterial drugs administered for several months [1–3]. The World Health
Organization (WHO) estimated 10.4 million of new cases of tuberculosis, in 2016, and 1.7 million died
from the disease, including HIV-positive patients [1]. Considering data reported to WHO and the
estimations of new cases of drug-resistance to first-line drugs, like rifampicin, isoniazid, ethambutol,
pyrazinamide or rifabutin becomes necessary develop improvements for anti-tuberculosis drugs [4].
The WHO establishes milestones to reduce the mortality caused by tuberculosis infections and
accelerate the decline of the infection, particularly when multidrug-resistance exists. Also, the increase
of highly resistant strains of tuberculosis makes it necessary for development of new drugs for
treatment of this epidemic disease [4].
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In recent years, green chemistry approaches have been considered for the development of new
drugs or improvement of their properties while at the same time help in the implementation of more
sustainable processes for their production. The preparation of therapeutic deep eutectic solvents
(THEDES) by incorporating the active pharmaceutical ingredient (API) in the system or solubilizing
the API in a previous synthesized eutectic mixture [5], is a sustainable preparation method that could
be used to improve bioavailability of the drugs. A eutectic mixture is defined as a combination of
two or more components in a certain molar ratio, that by hydrogen bonding form a new compound
characterized by a melting point depression, compared with the melting temperatures of the initial
compounds [5–9].
Currently available therapies for tuberculosis infections involve the combination of
four anti-tuberculosis drugs, namely isoniazid, rifampicin, ethambutol and pyrazinamide in the
first months and then the treatment continues with isoniazid and rifampicin [2–4,10]. Ethambutol is an
anti-tuberculosis drug that is bacteriostatic (inhibits the cell wall synthesis of bacteria) and helps to
prevent emergence of rifampicin resistance, when resistance to isoniazid is present [3,11]. Arginine is a
basic and semi-essential amino acid that is naturally ingested in diet. It was reported that arginine
reduces the symptoms associated to tuberculosis, in patients with tuberculosis and without HIV
infection. The supplementation with L-arginine could improve the immune system by increasing the
concentration of nitric oxide that acts as a cytotoxic substance in pathological processes. The high
levels of nitric oxide produced by arginine in T-helper lymphocytes type 1 (Th1), activate macrophages,
which are important cells in the immune response to tuberculosis infection. Studies demonstrate that
arginine could be useful as an adjunctive therapy for patients with tuberculosis and those, who are
mediated by the increase production of nitric oxide [12–14].
In this study, new THEDES based on ethambutol and L-arginine were prepared to enhance the
properties of these substances, particularly to increase their solubility, permeability and hence, in the
future, be able to lower any concentrations in the prescribed treatments.
2. Results
2.1. Polarized Optical Microscopy
The polarized optical microscopy (POM) was studied to observe the systems under polarized
light with a cross polarizer and to detect the existence of different phases in the eutectic mixtures.
We could observe black images in all samples (Figure 1), as well as characteristics of an amorphous
and homogeneous liquids without formation of crystals.
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2.2. Differential Scanning Calorimetry
As we can observe in Figure 2, the thermogram of the initial compounds present peaks of
endothermic events, in some of them we observe two peaks which could indicate different transition
stages between the crystalline and amorphous phases [6,8,15–17]. THEDES with ethambutol in liquid
phase does not present peaks at endothermic stage. In THEDES with L-arginine, a peak close to 100 ◦C
which is mostly due to water evaporation at this temperature, is observed.
The thermal behavior of these new compounds is characterized for THEDES with ethambutol,
which shows absence of peaks, as well as the formation of small peaks for THEDES with L-arginine,
which is due to the water evaporation. Consequently, the eutectic mixtures were successfully formed
and demonstrate the existence of interactions between the compounds that form THEDES by hydrogen
bonding [6].
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2.3. Nuclear Magnetic Resonance Studies
NMR spectroscopy was performed and 1H and 13C-NMR spectra (Table S2), HMBC and NOESY
in ethambu ol and THEDES with ethambutol was obtained, to explore possible inter ctions between
t e molecules that form THEDES, by hydrogen onding [18,19]. From 1H-NMR differenc s b tween
chemical shifts f the APIs and the THEDES were observed, mainly in the groups -NH of hambutol
that undergoes an upfield shift of 0.1 ppm f om the API to THEDES.
In ur study 1H-1H nuclear Overhauser spectroscopy (NOESY) was used to observe direct
intermolecular and intramolecula interactions in THEDES with ethambutol (Figure 3), as this
technique ide tifies spatially close protons. The NOESY spectrum shows in eractions between e -OH
of th -COOH groups of citric acid and the -OH and -NH groups of ethambutol (signal at 12.34 ppm);
at 9.14 ppm it can be n ticed tha the -NH groups of ethambutol are s atially close to the -OH groups
of ethambutol and -OH groups of citric acid. At 5.40 ppm th interacti n b tween the -OH groups of
ethambut l -NH group of ethambutol and the -OH groups of citric acid was observed. Furth rmore,
the spectrum shows an interaction between the -C-OH group of citric acid and the groups -OH and
-NH of ethambutol (signal at 5.15 ppm). Finally, strong interactio s b tween these groups and water is
also shown.
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2.4. Solubility and Permeability Studies
The study of solubility and permeability of the API and THEDES was evaluated in PBS, at 37 ◦C
to simulate physiological conditions. The results obtained are presented in the Table 1 and Figure 4.
Table 1. Solubility of APIs and THEDESs in PBS (pH 7.4), at 37 ◦C.
THEDES Molar Ratio Solubility (mg/mL)
Etha butol 4.64 ± 0.07
Citric Acid:Ethambutol:H2O 2:1:10 127.60 ± 0.69
L-Arginine 99.35 ± 0.54
Citric Acid:L-Arginine:H2O 1:1:6 102.17 ± 0.56
Citric Acid:L-Arginine:H2O 1:1:7 106.05 ± 0.12
Citric Acid:L-Arginine:H2O 2:1:7 105.89 ± 0.15
Citric Acid:L-Arginine:H2O 2:1:8 106.77 ± 0.49
itric cid:L- rginine: 2O 2:1:9 107.86 ± 0.33
We can observe an increase of the solubility of ethambutol in THEDES form of approximately
27.5 fold (from 4.64 mg/mL to 127.60 mg/mL), compared with ethambutol. However, in the case of
systems with L-arginine only a slight increase of solubility was observed compared to the pure API.
The permeability and diffusion coefficients were studied for the APIs and THEDES which
presented enhanced performance in the solubility studies and have some variability in molar ratios of
citric acid and water, with higher ratios of water. The assays were carried out using a commercially
available polyethersulfone (PES-U) membrane. A rapid diffusion rate was observed in the first minutes
and then the diffusion rate stabilizes. The permeability and the diffusion coefficient through the
membrane was estimated according to equations 1 and 2 and presented in Table 2.
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2.5. Biological Performance
In this work, we have evaluated the cell viability in the presence of the THEDES and the initial
compounds using a model Caco-2 cell line, that is originated from human colon epithelial cancer cell
line, and when cultured as a monolayer spontaneously acquires characteristics of mature enterocytes,
which is completed after 7 days of seeding. This characteristic model when grown to confluence could
mimic the human small intestine and might be used to test the intestinal permeability in vitro [20].
We observed through the assay with MTS for cell viability that citric acid is more toxic than
ethambutol, which contributes for the toxicity of THEDES systems (Figure 5).
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Table 3. IC50 of THEDES and raw materials in Caco-2 cell line.
THEDES Molar Ratio IC50 (M) pH
Ethambutol 0.1007 6.21
Citric Acid:Ethambutol:H2O 2:1:10 0.0647 5.61
Citric Acid 0.0033 7.08
L-Arginine 0.1017 10.43
Citric Acid:L-Arginine:H2O 1:1:6 0.0644 6.61
Citric Acid:L- rginine:H2O 1: :7 0.1085 5.88
Citric Acid:L- rginine:H2O 2: :7 0.0476 5.79
Citric Acid:L- rginine:H2O 2:1:8 0.0662 5.48
Citric Acid:L- rginine:H2O 2:1:9 0.0656 5.79
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3. Discussion
The preparation of novel eutectic systems continues to be a challenge because the mechanisms
that trigger the hydrogen bonding formation in the systems are not yet completely understood [6].
In this work, the aim was to produce therapeutic deep eutectic systems with anti-tuberculosis APIs
incorporated. After optimization, six different eutectic systems (Table S1) were obtained and clear and
transparent liquids at room temperature.
The THEDES were studied with POM and black images were observed, which indicates
amorphous and homogeneous liquids, without the formation of any solid crystals. In the thermogram
was evaluated by DSC and it well defined phase transitions of individual components were observed.
Around 100–120 ◦C, within THEDES phase transitions appear in the thermogram, which indicate
that these systems start to be unstable at these temperatures. This is attributed to the ratio of water
that evaporates from the systems at these temperatures. According to literature, the systems must
have melting temperatures below the melting peaks of the individual components [6,16]. In binary
mixtures these observations lead to the absence of melting peaks of each individual component in
DSC diagram [19,21]. The results obtained with DSC and POM indicate that systems are above the
respective liquid line on the phase diagram [6]. Dai and co-workers have found that small amounts
of water resulted in systems that are liquid at room temperature, reduce the time of preparation and
the temperature could decrease their viscosity. The stability of the DESs with small amounts of water,
generally is increased and the solubilizing capacity could also be tuned. However, adding superior
amounts of water (up to 50% of water content) could lead to dilution of DESs and results in a loss of
the existing hydrogen bonding, characteristic of these solvents [16,18,21]. In the case of the THEDES
herein reported, the presence of water is fundamental to the preparation of the systems.
With NMR studies we were able to study the structure of the compounds and confirm the
presence of citric acid and ethambutol in THEDES, by 1H and 13C-NMR, HMBC and NOESY.
Interactions between the compounds, particularly in the amine groups of ethambutol, were detected.
These presented a delocalization of the chemical shift (9.24 ppm to 9.14 ppm), which we hypothesized
that is due to interactions by hydrogen bonding formed with -OH of citric acid and water. In which
concerns the hydrogen bonded protons, changes in the chemical shift could be observed when THEDES
form a liquid structure, as we observed the upfield shift in the amine groups of ethambutol [5].
The solubility of the compounds is an important parameter for evaluating the features of the
THEDES prepared and observe if they are promising for future incorporation on medicines. In our
study was observed a significant increase of the solubility of ethambutol in the THEDES, however for
the systems containing L-arginine the difference was not so noticeable. In the case of the permeability
studies of the different compounds, similar behavior was observed. While the permeability of
ethambutol was increased in THEDES form, in case of arginine the THEDES presented a lower
permeability compared to the pure API. The diffusion coefficient of the systems presented the same
characteristic behavior of permeability, as higher diffusion coefficients means faster diffusion of the
compound through the membrane.
Duarte et al. described that a higher solubility leads to higher driving force through the membrane
in permeability studies [5], and our results also confirm this. As expected, the permeability and
diffusion coefficient of ethambutol in THEDES was higher, as its solubility is highly increased. This was
not the case in the systems with L-arginine.
The results obtained in solubility and permeability studies permit fit the THEDES in the
biopharmaceutics classification system and observe an increase of the properties of solubility and
permeability in THEDES with ethambutol. The parameters of biopharmaceutics classification system
are described in literature, and classifies the APIs in four different classes, since class I is high soluble
and high permeable; class II is low soluble and high permeable; class III is high soluble and low
permeable, and class IV is low soluble and low permeable [5]. An API is considered highly soluble
when the volume for dissolve 1 mg is lower than 250 mL, which we could verify in THEDES with
ethambutol that present a solubility of 127.6 mg/mL. A compound is considered highly permeable
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if presents permeability higher than 6 × 10−6 cm s−1 and the THEDES with ethambutol presented a
permeability of 128.3 × 10−5 cm s−1 that is higher than the reference value. According to literature and
the Biopharmaceutical Classification System (BCS), ethambutol is classified as a class III compound,
i.e., a compound with high solubility but low permeability. The results obtained in this work show that
THEDES can tailor the bioavailability of API’s and we can postulate that ethambutol can change
its classification from class III to class I, being in the THEDES form, highly soluble and highly
permeable [5,22].
The biological performance of the systems has shown a higher cytotoxicity of the THEDES in
respect to the pure API’s which is due to the presence of citric acid. In any case, as these experiments
demonstrate a dose-response they continue to be promising for anti-tuberculosis treatment as it
is possible to adjust the dosage required and decrease the dose due to the higher solubility and
permeability observed, particularly for the system containing ethambutol.
4. Materials and Methods
4.1. Materials
The reagents used for the preparation of THEDES were citric acid monohydrate (CA),
(CAS number 5949-29-1, ≥99.5% purity) obtained from PanReac AppliChem (Barcelona, Spain);
L-arginine (L-Arg), (CAS number 74-79-3, ≥98% purity) obtained from Sigma Aldrich
(St. Louis, MO, USA); and ethambutol (ETH), (CAS number 74-55-5, ≥98% purity) was obtained
from Alfa Aesar (Haverhill; MA, USA). The compounds were used without additional purification.
Phosphate buffer saline (PBS) were prepared as indicated in tablets of PBS by Fisher BioReagents
(Hampton, NH, USA), one tablet dissolved in 200 mL of deionized water, yielding a 0.01M phosphate
buffer, 0.0027 M potassium chloride, 0.137 M sodium chloride, pH 7.4 solution, at 25 ◦C.
4.2. Preparation of THEDES
Various systems with ethambutol and L-arginine in different combinations of molar ratios were
prepared (Table S1), however the mixtures indicated in the Table 4 were the ones that we observe to
form a stable eutectic mixture. The different components of the eutectic mixtures were weighed and
mixed, accordingly to different molar ratios, presented in Table 4. The THEDES were obtained by
heating the combination until 50/60 ◦C, under constant stirring (300 rpm) between 6 to 10 h, until a
clear liquid solution was formed [5,6].
Table 4. Different THEDES prepared.
Component A Component B Component C Molar Ratio Molar Mass *(g/mol) Abbreviation Visual Aspect
Citric Acid Ethambutol H2O 2:1:10 61.02 CA:ETH:H2O
Transparent liquid at
room temperature
Citric Acid L-Arginine H2O 1:1:6 61.56 CA:L-Arg:H2O
Citric Acid L-Arginine H2O 1:1:7 56.72 CA:L-Arg:H2O
Citric Acid L-Arginine H2O 2:1:7 77.02 CA:L-Arg:H2O
Citric Acid L-Arginine H2O 2:1:8 67.15 CA:L-Arg:H2O
Citric Acid L-Arginine H2O 2:1:9 63.06 CA:L-Arg:H2O
* MDES = Xsalt × Msalt + XHBD × MHBD, where X and M are mole fraction and molar mass, respectively [23].
4.3. Differential Scanning Calorimetry (DSC) Analysis—Thermal properties
The DSC experiments were performed using a DSC 131 instrument (Setaram, Tokyo, Japan)
operating with temperatures between −150 and +550 ◦C. The measurements were performed under
dry nitrogen atmosphere (at a flow rate of 50 mL min−1), with samples of 5–20 mg packed in hermetic
aluminium pans. The samples of initial compounds were equilibrated at 20 ◦C for 5 min, from 5 ◦C up
to 230 ◦C for ethambutol; for L-arginine up to 250 ◦C and for citric acid up to 170 ◦C; followed by an
isothermal period of 2 min, and cooling to the assay end temperature at a cooling rate of 10 ◦C min−1.
The samples with THEDES were equilibrated at 20 ◦C for 5 min, from 5 ◦C up to 230 ◦C for ethambutol
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systems and up to 260 ◦C for systems with L-arginine, followed by an isothermal period of 2 min,
and cooling to the assay end temperature at a cooling rate of 10 ◦C min−1.
4.4. Polarized Optical Microscopy (POM)
Optical characterization of the THEDES were carried out at room temperature using a transmission
mode of an BX-51 polarized optical microscope (Olympus, Tokyo, Japan) connected to an Olympus
KL2500 LCD cold light source. A droplet of THEDES was placed on a microscope glass slide and then
observed. The images were obtained with an equipped camera (Olympus DP73) and Olympus Stream
Basic 1.9 software (Olympus, Tokyo, Japan).
4.5. Nuclear Magnetic Resonance Studies (NMR)
All NMR spectra 1H and 13C were recorded at room temperature on a Bruker (Billerica, MA, USA)
spectrometer (400 MHz) and chemical shifts were referenced to SiMe4 (δ in ppm). The THEDES samples
were placed in a 5 mm NMR tube with deuterium dimethyl sulfoxide (DMSO-d6).
4.6. Solubility and Permeability Studies
The solubility studies were made with the pure APIs and THEDES. For performing these assays
were used a PBS solution, and was added an excess of API and THEDES to this solution, place
at 37 ◦C, under stirring for 24 h, for simulate physiological conditions. The determination of the
API solubility was made by UV spectroscopy in 1 mL quartz cuvettes, using a Lambda 35 UV/VIS
spectrometer (PerkinElmer, Villepinte, France) and the PerkinElmer UV WinLab software (PerkinElmer,
Villepinte, France). The absorbance of the solutions was measured at the maximum wavelength of
the respective API, 203 nm (ETH) and 211 nm (L-Arg). The calibration curve was made using the
respective APIs as standard for quantification.
For the permeability studies was used a glass Franz diffusion cells (PermeGear,
Hellertown, PA, USA) with 8 mL in the receptor compartment, 2 mL in the donor compartment and an
effective mass transfer area of 1 cm2. The membrane used was a polyethersulfone (PES-U) membrane,
with 150 µm thickness and 0.45 µm pore size (Sartorius Stedim Biotech, Goettingen, Germany).
The membrane was place between the receptor and donor compartment and held with a stainless-steel
clamp. The receptor compartment was filled with a PBS solution and the air bubbles were removed by
carefully tilting the Franz cells for the air bubbles to escape through the sampling arm. Then the donor
compartment was filled with the API or THEDES and 2 mL of PBS solution. The samples were taken
in intervals of 3, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 150 and 180 min, and the amount of diffused
API were measured by UV spectroscopy in 1 mL quartz cuvettes, using the Lambda 35 UV/VIS
spectrometer and the PerkinElmer UV WinLab software. The experiments were performed at 37 ◦C in
a water bath with stirring at 60 rpm, to eliminate the boundary layer effect. The permeability (P) of
APIs and THEDES was calculated by the following equation (Equation (1)):
− ln
(
1− 2Ct
C0
)
=
2A
V
× P× t (1)
where Ct is the concentration in the receptor compartment at time t, C0 is the initial concentration in the
donor compartment, V is the volume in two compartments, and A is the effective area of permeation.
The permeability coefficient can be calculated from the slope of the curve −(V/2A) * ln(1 -2Ct/C0)
versus t (cm s−1) [5,24,25].
The diffusion coefficient (D) of APIs and THEDES across the membrane was calculated according
to Fick’s Law of diffusion, following the equation (Equation (2)):
D =
V1V2
V1 +V2
× h
A
× 1
t
ln
(
C f − Ci
C f − Ct
)
(2)
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where D is the diffusion coefficient (cm2 s−1), Ci and Cf are the initial and final concentrations, and Ct
is the concentration at time t in the receptor compartment (mol L−1), V1 and V2 are the volume of
liquid in donor and receptor compartment, respectively (cm3), h is the thickness of the membrane (cm)
and A is the effective diffusion area of the membrane (cm2) [5,24,25].
4.7. In Vitro Cytotoxicity and IC50 Evaluation
For the evaluation of the biological performance of the THEDES, were made studies with Caco-2
cells, a human colon epithelial cancer cell line used as a model of human intestinal absorption of drugs
and other substances. Caco-2 cell line was provided by DSMZ (Braunschweig, Germany, ACC 169)
and was cultured in RPMI (1640 medium powder from Gibco, Lisboa, Portugal) supplemented
with 10% heat-inactivated fetal bovine serum (FBS) and 1% of antibiotic (penicillin-streptomycin).
Cells were maintained at 37 ◦C in a humidified incubator with 5% of CO2 [26]. Cell culture
medium and supplements were obtained from Gibco (Life Technologies—Alfagene, Lisboa, Portugal).
The cytotoxicity assay in Caco-2 cell line was performed after a culture period of 7 days, for the cells
achieve a monolayer of growth with approximately 80–90% confluence. Then the cells were seeded in
a 96-well culture plate and incubated with 100 µL of different concentrations of THEDES and initial
compounds, for 24 h. After the incubation time the cells were washed with PBS, and 100 µL of MTS
(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium bromide)
reagent (1:10 dilution) was added at each well and then incubated for 4 h, at 37 ◦C in 5% of CO2
atmosphere. The amount of formazan product was measured by absorbance at wavelength of 490 nm
with and Epoch Microplate Spectrophotometer (Bio-Tek Instruments, Winooski, VT, USA). The data
was expressed in percentage of cell viability with the control and the experiments were completed
with 3 independent experiments with three replicates.
The IC50 evaluation was determined with the percentage of cell viability at different concentrations
(between 0.01-1M), with successive dilutions of 1:2 starting in 1M of API or THEDES, using the
software GraphPad Prism 6.01 (Graphpad Software Inc., La jolla, San jose, CA, USA) (Figure S1,
Supplementary Material). The measurements of pH solutions were completed with a micropH 2001 of
Crison (Barcelona, Spain).
4.8. Statistical Analysis
The experiments were made in triplicates for each condition, being the data presented with
mean and standard deviation. The statistical analysis was performed using GraphPad Prism 6.01 and
following a parametric test (One-Way ANOVA with multiple comparisons to the control) or a t-test for
pairs of samples. Differences between experimental data were considered significant with a confidence
interval of 95%.
5. Conclusions
The evaluation and knowledge of these properties in the THEDES synthesized is essential
for further studies, namely the evaluation of the antimicrobial activity of theses THEDES and for
improving pre-existing drugs bioavailability and hence their administration regimens. This system
incorporating the API are a sustainable way to synthesize drugs and represent a progress to improve
pharmacokinetics of APIs and could provide new formulations. The systems with ethambutol and
CA:L-Arg:H2O (1:1:7) seems to be the more promising systems, due to their characteristics presented
by water content, solubility and cytotoxicity assays.
Supplementary Materials: The following are available online. Table S1: Different eutectic systems prepared,
during optimization process, Figure S1: IC50 graphs with log concentrations and cell viability used to determine
IC50, Table S2: Chemical shifts of 1H and 13C-NMR.
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